Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831371 | 1.00 | ALDH1A1 (0.57) | ALDH1A1SRD5A2KDM4EMAPTTDP2 | |
| Hydrochloric Acid SCHEMBL9256350 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SRD5A2KDM4EMAPTTDP2 | |
| Hydrochloric Acid SCHEMBL31085561 | 0.98 | ALDH1A1 (0.55) | ALDH1A1SRD5A2KDM4EMAPTTDP2 | |
| Furan SCHEMBL21525916 | 0.88 | ALDH1A1 (0.46) | ALDH1A1SRD5A2KDM4EMAPTTDP2 | |
| SCHEMBL30428318 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPT | |
| SCHEMBL1026101 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPT | |
| SCHEMBL29589725 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPT | |
| SCHEMBL1026913 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL22654009 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL15671006 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070282078-A1 | Synthesis of aryl N-acylurea from aryl isocyanates or aryl carbodiimides for use as intermediate in novel sequential self-repetitive reaction (SSRR) to form amides, amide-imides and their polymers | NATIONAL CHUNG HSING UNIVERSITY (TW) | 2007-12-06 | — | — | US | claimed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-119954810-A | Regulator of fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | ON TARGET LABORATORIES INC (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2024094163-A1 | POLYCYCLIC RING-FUSED DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024042007-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| CN-117229281-A | Di-parallel ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044029-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070282078-A1 | Synthesis of aryl N-acylurea from aryl isocyanates or aryl carbodiimides for use as intermediate in novel sequential self-repetitive reaction (SSRR) to form amides, amide-imides and their polymers | NATIONAL CHUNG HSING UNIVERSITY (TW) | 2007-12-06 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1756/4885SRD5A2 229/4885KDM4E 3451/4885 |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | ALDH1A1 1103/4885SRD5A2 561/4885KDM4E 585/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | ALDH1A1 2009/4885SRD5A2 2709/4885KDM4E 864/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ALDH1A1 1740/4885SRD5A2 222/4885KDM4E 3464/4885 |
| US-20240299590-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED DYES THEIR RELATED USES | FAP, FIBP, IK | ALDH1A1 442/4885SRD5A2 4803/4885KDM4E 2430/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | ALDH1A1 2009/4885SRD5A2 2709/4885KDM4E 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.